2020
DOI: 10.1111/jcmm.15156
|View full text |Cite|
|
Sign up to set email alerts
|

Abstract: In adults, glioma is the most commonly occurring and invasive brain tumour. For malignant gliomas, the current advanced chemotherapy includes TMZ (temozolomide). However, a sizeable number of gliomas are unyielding to TMZ, hence, giving rise to an urgent need for more efficient treatment choices. Here, we report that cyclin‐dependent kinases 4 (CDK4) is expressed at significantly high levels in glioma cell lines and tissues. CDK4 overexpression enhances colony formation and proliferation of glioma cells and ex… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 30 publications
(16 citation statements)
references
References 48 publications
(95 reference statements)
0
16
0
Order By: Relevance
“…Cyclin-dependent kinases 4 and 6 (CDK4/6) signalling regulates cell cycle, cell differentiation, metabolism and apoptosis. In glioma cells, CDK4 is overexpressed which led to glioma cell proliferation and TMZ resistance [ 260 ]. CDK4/6 inhibitors (palbociclib/PD 0332991, abemaciclib) specifically blocked the cell cycle at the G1-to-S transition phase, leading to cell cycle arrest and stopped cell proliferation [ 261 ].…”
Section: Results-glioblastoma Targeted Therapiesmentioning
confidence: 99%
“…Cyclin-dependent kinases 4 and 6 (CDK4/6) signalling regulates cell cycle, cell differentiation, metabolism and apoptosis. In glioma cells, CDK4 is overexpressed which led to glioma cell proliferation and TMZ resistance [ 260 ]. CDK4/6 inhibitors (palbociclib/PD 0332991, abemaciclib) specifically blocked the cell cycle at the G1-to-S transition phase, leading to cell cycle arrest and stopped cell proliferation [ 261 ].…”
Section: Results-glioblastoma Targeted Therapiesmentioning
confidence: 99%
“…Some PI3K inhibitors are currently undergoing clinical trials, such as GDC-0084, PX-866, pilaralisib, buparlisib, and XL765 [ 145 ]. Abemaciclib, palbociclib, and ribocyclib are examples of FDA (Food and Drug Administration)-approved oral drugs with good BBB permeability [ 146 , 147 ] that may be investigated for targeting CDK4/6.…”
Section: Facing a Real Challenge—drug Resistancementioning
confidence: 99%
“…Although many pro-proliferative genes were found as significantly upregulated upon CM treatment, a significantly diminished level of CDK4 was noteworthy. As in many other cancer cells, CDK4/6 inhibition was shown to inhibit the cellular proliferation of GBM cells (Cao et al, 2020). Decreased proliferation rate and viability of U87-CM treated LN229 cells might be connected with the downregulation of the CDK4 gene.…”
Section: Levels Of Both Pro-and Anti-proliferative Genes In U87 and Ln229 Cells Were Altered Following The CM Treatmentmentioning
confidence: 72%